Back

Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)

2 September 2024 (12:45 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular trends: hospitalisations, trials, and genetic therapies Trial Design ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Matthew Coggins

(United States of America)

3 More presentations in this session

Presentation thumbnail
Reassessing pharmacological trials with positive composite outcome driven by reduction in nonfatal myocardial infarction: a systematic review and meta-analysis
Mr H. Sun (CN)
Abstract Slides Video
Presentation thumbnail
Association between autonomic dysfunction, 12-year mortality and 10-year incident cardiovascular disease
Doctor B. Hernandez (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
First trimester maternal infections and offspring congenital heart defects: a systematic review and meta-analysis
Miss H. Su (Leuven, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular trends: hospitalisations, trials, and genetic therapies
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 12:45 CET
You may be interested in
thumbnail
Congress Presentation
Genetic therapies in inherited cardiomyopathies
thumbnail
Congress Presentation
Gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT): IND-enabling data and design of the ARTEMIS Phase 1b clinical trial
thumbnail
Congress Session
Cardiovascular trends: hospitalisations, trials, and genetic therapies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources